Exelixis, Inc. (EXEL)
41.39
+0.32
(+0.78%)
USD |
NASDAQ |
Dec 11, 16:00
41.36
-0.03
(-0.07%)
Pre-Market: 20:00
Exelixis Research and Development Expense (TTM): 860.76M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vanda Pharmaceuticals, Inc. | 100.10M |
| ADMA Biologics, Inc. | 3.776M |
| Aldeyra Therapeutics, Inc. | 35.99M |
| Merck & Co., Inc. | 14.26B |
| ACADIA Pharmaceuticals, Inc. | 344.78M |